A particularly exciting example is a C-X-C chemokine receptor type 4 (CXCR4) antagonist peptide-docetaxel conjugate, which self-assembles into nanoparticles targeting CXCR4-overexpressing metastatic tumors. Here, CXCR4 is linked to metastatic neoplasm.